Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 388

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 388
---
 Following the Conversion, the Sponsor held an aggregate
of 5,296,246 shares of Class A common stock, all of which are subject to the Sponsor Support Agreement.

CERo Support Agreements

In connection with the execution of the Business
Combination Agreement, certain CERo stockholders (the “CERo Supporting Stockholders”) entered into support agreements with
CERo (the “CERo Support Agreements”). Under the CERo Support Agreements, each CERo Supporting Stockholder agreed as promptly
as practicable following the time at which the Registration Statement/Proxy Statement shall have been declared effective and made available
to such CERo Supporting Stockholders, to execute and deliver a written consent with respect to all outstanding shares of CERo common
stock and CERo preferred stock held by such CERo Supporting Stockholder (the “Subject CERo Shares”) approving the Business
Combination Agreement and the transactions contemplated thereby (including the Business Combination). In addition to the foregoing, each
CERo Supporting Stockholder agreed that, at any meeting of the holders of CERo capital stock, each such CERo Supporting Stockholder will
appear at the meeting, in person or by proxy, and cause its Subject CERo Shares to be counted as present thereat for purposes of calculating
a quorum and voted (i) to approve and adopt the Business Combination Agreement, the transactions contemplated thereby (including
the Business Combination), and any other matters necessary or reasonably requested by CERo for consummation of the Business Combination,
and (ii) against any proposal that conflicts or materially impedes or interferes with, or would adversely affect or delay, the consummation
of the transactions contemplated by the Business Combination Agreement (including the Business Combination).

Note 7 — Stockholders’ Deficit

Common Stock

Class A common stock —
The Company is authorized to issue 60,000,000 shares of Class A common stock with a par value of $0.0001 per share. As of December
31, 2023 and 2022, there were 5,481,250 and 885,000 shares of Class A common stock issued and outstanding (excluding 764,957 and
1,288,298 shares subject to possible redemption), respectively.

Class B common stock —
The Company is authorized to issue 10,000,000 shares of Class B common stock with a par value of $0.0001 per share